Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate ensovibep in NIH-Sponsored ACTIV-3 Trial

ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021
Ensovibep to be first … [+9816 chars]read more

Leave a Comment